Steve Myatt
Chief Executive Officer

PhD

Steve is a Partner at Sixth Element Capital LLP, which manages the $100m oncology focused venture fund, the CRT Pioneer Fund LP (CPF). As part of this team Steve has been integral in the identification and funding of thirteen investments and the licensing of two projects to Sierra Oncology and Boston Pharmaceuticals. He is currently serving as Azeria’s Chief Executive Officer. In his role at Sixth Element Capital, Steve has successfully managed CPF investments through the investment cycle from early discovery to first in human Phase I clinical trials and partnering. Steve also has significant technology transfer transactional experience and was formerly Head of Alliances, Business Development, at Cancer Research Technology. In this role Steve was responsible for identifying and establishing multi-centre drug discovery partnerships between industry and academia in under-explored areas of cancer biology. Steve has a first-class degree in Pharmacology, a Ph.D. in paediatric oncology, and has published in journals such as Cancer Research, Clinical Cancer Research, and Nature Reviews Cancer.